Efficacy and tolerability of initial triple combination therapy with metformin, dapagliflozin and saxagliptin compared with stepwise add-on therapy in drug-naïve patients with type 2 diabetes (TRIPLE-AXEL study): A multicentre, randomized, 104-week, open-label, active-controlled trial.
Nam Hoon KimJun Sung MoonEun Young LeeHo Chan ChoSoo Heon KwakSoo LimMin Kyong MoonDong-Lim KimTae Ho KimEunvin KoJuneyoung LeeSin Gon KimPublished in: Diabetes, obesity & metabolism (2024)
Among newly diagnosed patients with T2D, initial TCT effectively lowered HbA1c levels with higher tolerability and safety than SAT for 104 weeks, suggesting a novel strategy for initial combination therapy in T2D patients.
Keyphrases
- combination therapy
- open label
- newly diagnosed
- double blind
- placebo controlled
- clinical trial
- phase iii
- phase ii
- study protocol
- phase ii study
- end stage renal disease
- chronic kidney disease
- ejection fraction
- peritoneal dialysis
- stem cells
- randomized controlled trial
- prognostic factors
- patient reported outcomes
- emergency department
- mesenchymal stem cells
- smoking cessation
- radiation therapy
- drug induced
- rectal cancer